In the study, a total of 249 advanced/metastatic melanoma patients with performance status 0–1 based on the Eastern Cooperative Oncology Group (ECOG) were admitted to monotherapy with anti-PD-1. The gene discussed is PDCD1; the disease is metastatic melanoma.